Is EXEL stock a Buy, Sell, or Hold?

Based on our analysis, EXEL is currently a WAIT with low confidence. 📊 MIXED SIGNALS: EXEL shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of EXEL stock?

Our analysis estimates the fair value range for EXEL to be between $52.38 and $56.96. The current price is $59.01.

What is the analyst price target for EXEL?

The average Wall Street analyst price target for EXEL is $53.69. This implies a potential upside of -9.0% from current levels.

EXEL Stock Analysis: Buy, Sell, or Hold?

EXEL - Exelixis Inc

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

$59.01

-0.12 (-0.20%) ▼

5d: +8.37%

30d: +13.05%

90d: +11.97%

WAIT

LOW Confidence

Protect Your EXEL Gains

Analysis Updated: Sep 4, 2026 12:00 AM ET

Earnings: Aug 05, 2026 0d

Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Sep 2, 2026 at $58.53 · last confirmed Sep 4, 2026

Strength: 8.7/10

Get Alerted When EXEL Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: EXEL shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 19.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$91.27

Based on 11.5% avg growth

INTRINSIC VALUE TODAY

$56.67

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: EXEL is currently trading at $59.01, which is considered extended relative to its 30-day fair value range of $52.38 to $56.96. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.8) compared to its historical average (12.5). At these levels, the market is pricing in 3.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, EXEL is in a strong uptrend. The price is approaching resistance at $59.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: EXEL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $52.38 - $56.96

Company Quality Score 32/100 (SELL)

Volume Confirmation HIGH

Confidence Score 22.4%

Protect Your Profits

Holding EXEL? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
BEARISH: Weak technical setup (15/100)
BULLISH: High volume confirmation
BEARISH: Trading above Wall St target ($53.69)
NEUTRAL: Market pricing in 3.5% annual earnings growth - fairly valued
WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $52.38 - $56.96

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $53.39

Resistance Level $59.72

Current Trend Strong Uptrend

Technical data as of Sep 4, 2026

Fundamental Context

Forward P/E (Next Year Est.) 13.85

Wall Street Target $53.69 (-9.0%)

Revenue Growth (YoY) 10.6%

Earnings Growth (YoY) 26.2%

Profit Margin 35.3%

Valuation Premium vs History +3.5% premium

PE vs Historical 13.9 vs 12.5 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +3.5% (market-implied from PE analysis)

1-Year Target $61.08 (+4%)

2-Year Target $63.21 (+7%)

3-Year Target $65.43 (+11%)

3-Yr Target (if PE normalizes) (PE: 14→13) PE COMPRESSION $59.05 (+0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.2, Growth: 19.0%) $145.11 (+146%)

Base: (SPY PE: 13.8, Growth: 19.0%) $99.34 (+68%)

Bear: (PE: 11.8, Growth: 19.0%) $84.44 (+43%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.

Trailing PE: 18.59 | Current EPS (TTM): $3.18

Bull Case $87.15 (+48%)

Analyst growth 34.0%, PE expands to 20.5

Base Case $79.23 (+34%)

Market implied 34.0%, PE stable at 18.6

Bear Case $40.21 (-32%)

Severe decline -20.0%, PE contracts to 15.8

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: September 04, 2026 10:39 PM ET
Data refreshes hourly during market hours. Next update: 11:39 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is EXEL showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for EXEL.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
XENE Xenon Pharmaceuticals Inc	STRONG BUY 19 analysts	$81	56 HOLD
RARE Ultragenyx	STRONG BUY 20 analysts	$55	45 HOLD
VKTX Viking Therapeutics Inc	STRONG BUY 19 analysts	$92	48 HOLD
RCKT Rocket Pharmaceuticals I…	STRONG BUY 18 analysts	$9	35 SELL
BEAM Beam Therapeutics Inc	STRONG BUY 17 analysts	$52	50 HOLD

XENE Xenon Pharmaceuti…

56 HOLD

RARE Ultragenyx

45 HOLD

VKTX Viking Therapeuti…

48 HOLD

RCKT Rocket Pharmaceut…

35 SELL

BEAM Beam Therapeutics…

50 HOLD

Advanced EXEL Option Strategies

Professional options setups generated by AI based on today's EXEL price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for EXEL

EXEL Technical Chart EXEL Price Prediction EXEL Earnings Date EXEL Investment Advisor EXEL Fair Price Analyzer EXEL Options Advisor EXEL Options Chain EXEL Options Analysis EXEL Competitors

Compare EXEL with Peers

EXEL vs INCY
Which one to buy?

EXEL vs BMRN
Which one to buy?

EXEL vs ACAD
Which one to buy?

EXEL vs VRTX
Which one to buy?

EXEL vs NBIX
Which one to buy?

Create New Comparison View All Competitors

Tradestie